

**Science Board to the Food and Drug Administration
FDA White Oak Campus, Building 31, The Great Room (Rm. 1503)
10903 New Hampshire Ave, Silver Spring, Maryland 20993
November 15, 2016**

AGENDA

- 8:30 a.m. Opening Introductions**
Bruce Psaty, MD, PhD, MPH, Science Board Chair
- 8:45 a.m. Conflict of Interest**
Rakesh Raghuwanshi, MPH, Designated Federal Officer, Science Board, FDA
- 8:50 a.m. Commissioner's Remarks**
Robert Califf, MD, Commissioner of Food and Drugs, FDA
- 9:00 a.m. Chief Scientist's Remarks**
Luciana Borio, MD, Acting Chief Scientist, FDA
- 9:15 a.m. Final Report – Scientific Engagements Subcommittee**
Scott Steele, PhD, Subcommittee Chair
- 9:45 a.m. Progress Update on Bovine Heparin Initiative**
David Keire, PhD (CDER), and Luisa Gregori, PhD (CBER), FDA
- 10:15 a.m. Progress Update on Opioid Action Plan**
Douglas Throckmorton, MD, Deputy Director for Regulatory Programs, CDER, FDA
- 10:45 a.m. Break**
- 11:00 a.m. Response to the Commissioner's Fellowship Program Evaluation Report**
Leslie Wheelock, MS, RN, Director, Office of Scientific Professional Development, FDA
- 11:30 a.m. Final Report – ORA Food Emergency Response Network Cooperative Agreement Program Evaluation Subcommittee**
Barbara Kowalcyk, PhD, Subcommittee Chair
- 12:00 p.m. Lunch (on your own)**
- 1:00 p.m. NARMS Update and Request for Subcommittee to Review**
Heather Tate, PhD, MS, Epidemiologist, Center for Veterinary Medicine, FDA
- 1:30 p.m. Gene Editing**
Peter Marks, MD, Director, CBER
- 2:00 p.m. Visioning CBER Research in 2025**
Carolyn Wilson, PhD, Associate Director for Research, CBER
- 2:30 p.m. CBER Response to the Post-marketing Safety Review Report**
Richard Forshee, PhD, Associate Director for Research, CBER
- 3:00 p.m. Open Public Hearing**
- 4:00 p.m. Closing Comments**
Bruce Psaty, MD, PhD, MPH, Science Board Chair